ReviewAnnals of medicine2025
Exploring the significance of fatty acid metabolism reprogramming in the pathogenesis of cancer and anticancer therapy.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of post-revascularization stroke in Moyamoya disease: A systematic review, meta-analysis, and meta-regression.Neurosurgical review · 2026Pooled it
- Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies.iScience · 2026Review
- A novel aurora kinase molecular glue-based degrader sp-2-067 inhibits prostate cancer cell growth and alters immune profile.Investigational new drugs · 2026Article
- Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- Potential Ferroptosis-Related Genes and Immune Infiltration in Form-Deprivation Myopia: An Integrative Bioinformatics and in vitro Validation Study.International journal of general medicine · 2026Article
- FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.Oncology research · 2026Article
- A design-of-experiments strategy for engineering 3D topographical features in osteosarcoma modelling.Materials today. Bio · 2025Article
- Polyphenols in Pancreatic Cancer Management: Exploring the Roles and Mechanisms of Resveratrol and Epigallocatechin.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the important markers that distinguish tumor cells from normal cells is metabolic reprogramming. Among them, the reprogramming of fatty acid metabolism not only supports the fuel supply for energy but also meets the needs of rapid biosynthesis, providing selective growth advantages for tumor cells to resist harsh microenvironments. Due to the crucial role of fatty acid metabolic reprogramming in tumor metabolism, its various functions in cancer have attracted more and more attention. In this review, we summarize the mechanisms of fatty acid metabolic reprogramming in tumor cells and the series of responses (such as active ferroptosis signaling), analyze the potential impacts brought by fatty acid metabolic reprogramming in various human cancers and focus on the significance of targeting fatty acid metabolic pathways and dietary control in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.